医学
血糖性
医疗补助
胰岛素释放
1型糖尿病
糖尿病
2型糖尿病
血糖
内科学
破折号
儿科
内分泌学
医疗保健
计算机科学
经济
经济增长
操作系统
作者
Gregory P. Forlenza,Daniel J. DeSalvo,Grazia Aleppo,Emma G Wilmot,Cari Berget,Lauren M. Huyett,Irene Hadjiyianni,Jadell Mendez,Lindsey R. Conroy,Trang T. Ly,Jennifer L. Sherr
出处
期刊:Diabetes Technology & Therapeutics
[Mary Ann Liebert]
日期:2024-02-16
标识
DOI:10.1089/dia.2023.0578
摘要
Background: The Omnipod® 5 Automated Insulin Delivery System was associated with favorable glycemic outcomes for people with type 1 diabetes (T1D) in two pivotal clinical trials. Real-world evidence is needed to explore effectiveness in nonstudy conditions. Methods: A retrospective analysis of the United States Omnipod 5 System users (aged ≥2 years) with T1D and sufficient data (≥90 days of data; ≥75% of days with ≥220 continuous glucose monitor readings/day) available in Insulet Corporation's device and person-reported datasets as of July 2023 was performed. Target glucose setting usage (i.e., 110–150 mg/dL in 10 mg/dL increments) was summarized and glycemic outcomes were examined. Subgroup analyses of those using the lowest average glucose target (110 mg/dL) and stratification by baseline characteristics (e.g., age, prior therapy, health insurance coverage) were conducted. Results: In total, 69,902 users were included. Multiple and higher glucose targets were more commonly used in younger age groups. Median percentage of time in range (TIR; 70–180 mg/dL) was 68.8%, 61.3%, and 53.6% for users with average glucose targets of 110, 120, and 130–150 mg/dL, respectively, with minimal time <70 mg/dL (all median <1.13%). Among those with an average glucose target of 110 mg/dL (n = 37,640), median TIR was 65.0% in children and adolescents (2–17 years) and 69.9% in adults (≥18 years). Subgroup analyses of users transitioning from Omnipod DASH or multiple daily injections and of Medicaid/Medicare users demonstrated favorable glycemic outcomes among these groups. Conclusion: These glycemic outcomes from a large and diverse sample of nearly 70,000 children and adults demonstrate effective use of the Omnipod 5 System under real-world conditions.
科研通智能强力驱动
Strongly Powered by AbleSci AI